Mutations in the epidermal growth factor receptor (EGFR) kinase domain are the oncogenic drivers of this adenocarcinoma. Tyrosine kinase inhibitors (TKIs), developed over the last two decades, targeting EGFR mutations, […]
The third-generation EGFR inhibitor, Osimertinib (Tagrisso, AZD9291), was approved by the Chinese Food and Drug Administration (NMPA) recently for first-line treatment of patients with EGFR mutation-positive advanced or metastatic non-small cell lung […]
The prognosis of patients with early lung cancer is better, but many patients with lung cancer are diagnosed with advanced stage, and the overall five-year survival rate is only about […]
Introduction of EGFR EGFR is the expression product of proto-oncogene C-ERBB1, the receptor of EGF cell proliferation and signal transduction. It is a member of epidermal growth factor receptor (HER) […]
Although the role of autophagy in cancer is very complex, various pharmacological agents with different antineoplastic properties have been shown to induce autophagic activity resulting in massive death of cells […]